Testing new treatments for early breast cancer
Part of Cancer, Skin clinical trials.
This trial tests new treatments for early breast cancer (stage II or III). It aims to find better therapies that can stop the cancer from coming back, and you may receive a promising new drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have invasive breast cancer (confirmed by biopsy).
- Your cancer must be stage II or III (not spread to distant organs).
- You must be able to do your daily activities with little or no help (ECOG 0 or 1).
- Your age must be between 18 and 80.
- You cannot be on long-term steroids or immune-suppressing drugs, have a history of lung scarring, or have an active infection or another recent cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatment given before surgery for certain stage IIb–IIIc breast cancers. It uses results from your tumor to guide the treatment plan and aims to improve how well the therapy works before the operation.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
This trial studies a standard follow-up treatment plan that combines chemotherapy and radiation after surgery, and it looks for blood/tissue “biomarkers” that predict who benefits most. If you have high-risk breast cancer that didn’t fully disappear after initial (neoadjuvant) chemo, you may be eligible to help guide better future treatment choices.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This trial tests whether giving less chemotherapy is safe when patients have high levels of tumor-infiltrating lymphocytes (TILs) — a sign that the body's immune system is already fighting the cancer. It is for women with early-stage, triple-negative breast cancer.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.